Precocious Puberty

Updated: July 15, 2024

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

histrelin

age: >2 years
50 mg implant given SC for every 12 months
The maximum duration of treatment includes removing the implant after 12 months

leuprolide

<2 years old: Safety and efficacy not determined
For Lupron Depot-Ped
<25 kg: administer dose of 7.5 mg intramuscularly monthly
>25 kg to 37.5 kg: administer dose of 11.25 mg intramuscularly monthly
>37.5 kg: administer dose of 15 mg intramuscularly monthly
For Lupron Depot-Ped
Administer dose of 11.25 mg intramuscularly injection in each 3 months
For Lupron Depot-Ped
Administer dose of 45 mg intramuscularly in each 6 months
For Fensolvi
Administer dose of 45 mg subcutaneously once in each 6 months
For Leuprolide acetate
50 mcg/kg daily subcutaneously and that can be increased by 10 mcg/kg daily, if downregulation is not reached
Dosage Modifications
Renal or hepatic impairment
Study not performed
Dosing Considerations
Periodically measure the height and bone age in accordance with the specific product recommendations

leuprorelin

As aqueous injection: If total down-regulation is not achieved, the initial dose of 50 mcg/kg daily by subcutaneous injection may be increased by 10 mcg/kg/day. Preparations for the depot: Initial dose: 0.3 mg/kg/dose (a minimum dose: 7.5 mg) administered intravenously every 4 weeks; this equals to 7.5 mg for children below 25 kg, 11.25 mg for children between 25 and 37.5 kg, and 15 mg for children above 37.5 kg. When down-regulation is not achieved, the dose may be increased during maintenance in 3.75 mg increments every four weeks. Before the age of 11 (for females) and 12 (for males), consider discontinuing therapy

Future Trends